-Reuters WASHINGTON: World Bank President Jim Yong Kim called for a commitment by the international community on Tuesday to end extreme poverty by 2030 and to improve the lives of the most vulnerable people living in developing countries. To reach that goal, Kim said the world need to reduce the number of people living below the poverty line of $1.25 per day to 3 percent globally by 2030, and raise the per...
More »SEARCH RESULT
Total Matching Records found : 2119
When innovation is under threat-Swati Piramal
-The Financial Express A patent law that is transparent, based on principles of good science & encourages innovation is in India's interest In 500 BC, in the Greek city of Sybaris, it was proclaimed that "encouragement was held out to all who should discover any new refinement in luxury, the profits arising from which were secured to the inventor by patent for the space of a year." England followed with the Statute...
More »Novartis patent case: Glivec developer Brian Druker hails SC ruling- Chidanand Rajghatta
-The Economic Times WASHINGTON: Big Pharma found little support from the small guy on the street as the Indian Supreme Court's decision to reject patent claims of the drug maker Novartis for its celebrated cancer medicine Glivec reverberated across the world. The pharma lobby railed against the decision but the overwhelming sentiment, from physicians to politicians, from academia to media, particularly in a country groaning from the high cost of health care,...
More »Rx: Make All Clinical Trial Data Public
-The Economic Times Should drug companies make clinical trials data public? All over the world, drug regulators are increasingly in favour of doing so, much to the discomfort of pharmaceutical companies, and the London-based European Medicines Agency (EMA) is the first mover in this regard. As the journal Nature reports, EMA is likely to do so by next year, at least for some clinical trials data. On April 19, all the...
More »Supreme Court rules for cheap cancer drug -Subodh Varma
-The Times of India The Supreme Court on Monday rejected pharma giant Novartis AG's plea to preserve its patent over a life-saving cancer drug, Glivec, drawing a huge sigh of relief from thousands of patients in India and in dozens of developing countries as the fear of an almost 15-fold escalation of drug costs receded. It is the biggest setback for multinational pharma companies, which have been denied patent protection...
More »
